Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.
The biomarker assay can be used potentially to enrich clinical trials and monitor patients' disease activity and treatment response.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback